PK Study of T-817 in Subjects With Hepatic Impairment

Completed · Phase 1

Conditions studied: Healthy, Hepatic Impairment

In brief

The primary objective is to determine the single-dose pharmacokinetics (PK) of T-817 and T-817M5 (metabolite of T-817) in subjects with mild, moderate or severe hepatic impairment compared to matched healthy control subjects. The secondary objective is to determine the safety and tolerability of single-dose T -817MA (Maleate salt of T-817) in subjects with mild, moderate or severe hepatic impairment.

Key facts

Study ID
NCT02693197
Run by
FUJIFILM Toyama Chemical Co., Ltd.
People needed
36
Starts
2016-02-01
Expected to finish
2016-08-01
Last updated by the study team
2017-11-24

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.